Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Shares of Biogen Inc. BIIB shed 1.44% to $141.00 Wednesday, on what proved to be an all-around positive trading session for ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 14.Stay Ahead of the ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...